These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 24346133)
1. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia. Bentsen H; Osnes K; Refsum H; Solberg DK; Bøhmer T Transl Psychiatry; 2013 Dec; 3(12):e335. PubMed ID: 24346133 [TBL] [Abstract][Full Text] [Related]
2. Neurocognitive effects of an omega-3 fatty acid and vitamins E+C in schizophrenia: A randomised controlled trial. Bentsen H; Landrø NI Prostaglandins Leukot Essent Fatty Acids; 2018 Sep; 136():57-66. PubMed ID: 29079039 [TBL] [Abstract][Full Text] [Related]
3. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids. Amminger GP; Mechelli A; Rice S; Kim SW; Klier CM; McNamara RK; Berk M; McGorry PD; Schäfer MR Transl Psychiatry; 2015 Jan; 5(1):e495. PubMed ID: 25585167 [TBL] [Abstract][Full Text] [Related]
4. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987 [TBL] [Abstract][Full Text] [Related]
5. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. Pawełczyk T; Grancow-Grabka M; Kotlicka-Antczak M; Trafalska E; Pawełczyk A J Psychiatr Res; 2016 Feb; 73():34-44. PubMed ID: 26679763 [TBL] [Abstract][Full Text] [Related]
6. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Arvindakshan M; Ghate M; Ranjekar PK; Evans DR; Mahadik SP Schizophr Res; 2003 Aug; 62(3):195-204. PubMed ID: 12837515 [TBL] [Abstract][Full Text] [Related]
7. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial. Emsley R; Niehaus DJ; Oosthuizen PP; Koen L; Ascott-Evans B; Chiliza B; van Rensburg SJ; Smit RM Psychiatry Res; 2008 Dec; 161(3):284-91. PubMed ID: 18962989 [TBL] [Abstract][Full Text] [Related]
8. Omega-3 fatty acids reduce cardiometabolic risk in first-episode schizophrenia patients treated with antipsychotics: Findings from the OFFER randomized controlled study. Pawełczyk T; Grancow-Grabka M; Żurner N; Pawełczyk A Schizophr Res; 2021 Apr; 230():61-68. PubMed ID: 33684737 [TBL] [Abstract][Full Text] [Related]
9. An increase in plasma brain derived neurotrophic factor levels is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: secondary outcome analysis of the OFFER randomized clinical trial. Pawełczyk T; Grancow-Grabka M; Trafalska E; Szemraj J; Żurner N; Pawełczyk A Psychopharmacology (Berl); 2019 Sep; 236(9):2811-2822. PubMed ID: 31098654 [TBL] [Abstract][Full Text] [Related]
10. Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods. Pawełczyk T; Grancow M; Kotlicka-Antczak M; Trafalska E; Gębski P; Szemraj J; Żurner N; Pawełczyk A BMC Psychiatry; 2015 May; 15():97. PubMed ID: 25934131 [TBL] [Abstract][Full Text] [Related]
11. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study. Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269 [TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms. Hsu MC; Huang YS; Ouyang WC Lipids Health Dis; 2020 Jul; 19(1):159. PubMed ID: 32620164 [TBL] [Abstract][Full Text] [Related]
13. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Emsley R; Chiliza B; Asmal L; du Plessis S; Phahladira L; van Niekerk E; van Rensburg SJ; Harvey BH Schizophr Res; 2014 Sep; 158(1-3):230-5. PubMed ID: 24996507 [TBL] [Abstract][Full Text] [Related]
14. Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia. Jamilian H; Solhi H; Jamilian M Glob J Health Sci; 2014 Sep; 6(7 Spec No):103-8. PubMed ID: 25363186 [TBL] [Abstract][Full Text] [Related]
15. Nutrient supplementation with polyunsaturated fatty acids and micronutrients in rheumatoid arthritis: clinical and biochemical effects. Remans PH; Sont JK; Wagenaar LW; Wouters-Wesseling W; Zuijderduin WM; Jongma A; Breedveld FC; Van Laar JM Eur J Clin Nutr; 2004 Jun; 58(6):839-45. PubMed ID: 15164103 [TBL] [Abstract][Full Text] [Related]
16. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Amminger GP; Schäfer MR; Papageorgiou K; Klier CM; Cotton SM; Harrigan SM; Mackinnon A; McGorry PD; Berger GE Arch Gen Psychiatry; 2010 Feb; 67(2):146-54. PubMed ID: 20124114 [TBL] [Abstract][Full Text] [Related]
17. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Peet M; Brind J; Ramchand CN; Shah S; Vankar GK Schizophr Res; 2001 Apr; 49(3):243-51. PubMed ID: 11356585 [TBL] [Abstract][Full Text] [Related]
18. Omega-3 fatty acids for postoperative atrial fibrillation: alone or in combination with antioxidant vitamins? Guo XY; Yan XL; Chen YW; Tang RB; Du X; Dong JZ; Ma CS Heart Lung Circ; 2014 Aug; 23(8):743-50. PubMed ID: 24685324 [TBL] [Abstract][Full Text] [Related]